4K – koksyby w codziennej praktyce – komu, kiedy i który? Dyskusja
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2018
Słowa kluczowe:
koksyby, wskazania, działania niepożądane, preferencje
##plugins.themes.bootstrap3.article.main##
Abstrakt
Koksyby, jako selektywne inhibitory cyklooksygenazy typu 2, wykazują silne działanie przeciwbólowe i przeciwzapalne. Ze względu na mechanizm działania wywołują zdecydowanie mniej skutków ubocznych związanych z przewodem pokarmowym i generalnie nie wymagają równoległego stosowania inhibitorów pompy protonowej. W świetle najnowszych danych obawy przed toksycznym działaniem koksybów na układ krążenia nie znajdują potwierdzenia. Wysoka skuteczność i mała liczba działań niepożądanych czyni je lekami preferowanymi u chorych z uprzednimi powikłaniami ze strony przewodu pokarmowego, z czynnikami ryzyka ich wystąpienia, ale także u osób starszych stosujących równocześnie wiele innych leków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grodzicki , T., & Tłustochowicz , W. (2018). 4K – koksyby w codziennej praktyce – komu, kiedy i który? . Medycyna Faktów , 11(1(38), 84-89. https://doi.org/10.24292/01.MF.0118.13
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Bannuru R., Schmid C., Kent D. et al.: Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann. Intern. Med. 2015; 162: 46-54.
2. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769-779.
3. Boltem W.W.: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006; 65: 7-13.
4. Brænne I., Willenborg C., Tragante V. et. al.: A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci. Rep. 2017; 7: 10252.
5. Chan F., Lanas A., Scheiman J. et al.: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
6. Collantes E., Curtis S, Lee K. et al.; for the Etoricoxib Rheumatoid Arthritis Study Group: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002; 3: 10.
7. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432.
8. da Costa B., Reichenbach S., Keller N. et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387: 2093-2105.
9. Croom K., Siddiqui A.: Etoricoxib. A Review of its Use in the Symptomatic Treatment of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and Acute Gouty Arthritis. Drugs 2009; 69(11): 1513-1532.
10. Feng X., Tian M., Zhang W. et. al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13(1): e0190798.
11. van der Heijde D., Ramiro S., Landewé R. et. al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76(6): 978-991.
12. Lanas A., Boers M, Nuevo J.: Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann. Rheum. Dis. 2015; 74: 675-681.
13. MacDonald T., Hawkey C., Ford I. et al.: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur. Heart J. 2017; 38: 1843-1850.
14. Matsumoto A., Melian A., Mandel D. et. al.; and the Etoricoxib Rheumatoid Arthritis Study Group: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol. 2002; 29: 1623-1630.
15. Moore R., Derry S, Aldington D. et. al.: Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2015; (9): CD008659.
16. Nissen S., Yeomans N., Solomon D. et al.: Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 2016; 375: 2519-2529.
17. Puopolo M., Boice J., Fidelholtz J. et. al.: A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with Osteoarthritis. Osteoarthritis Cartilage 2007; 15: 1348-1356.
18. Richy F., Bruyere O., Ethgen O. et al.; on behalf of the WHO Collaborating Centre for Public Health Aspects of Osteoarticular Disorders, Liège, Belgium: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann. Rheum. Dis. 2004; 63: 759-766.
19. Ruschitzka F., Borer J., Krum H. et. al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
20. Scott P., Kingsley G., Smith C. et al.: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis. 2007; 66: 1296-1304.
21. Silverstein F., Faich G., Goldstein J. et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
22. Stam W., Jansen J., Taylor S.: Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison. Open Rheumatol. J. 2012; 6: 6-20.
23. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
24. Zhang W., Moskowitz R., Nuki G. et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based, expert consensus Guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
2. Bhala N., Emberson J., Merhi A. et al.; Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013; 382(9894): 769-779.
3. Boltem W.W.: Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2006; 65: 7-13.
4. Brænne I., Willenborg C., Tragante V. et. al.: A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors. Sci. Rep. 2017; 7: 10252.
5. Chan F., Lanas A., Scheiman J. et al.: Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 2010; 376: 173-179.
6. Collantes E., Curtis S, Lee K. et al.; for the Etoricoxib Rheumatoid Arthritis Study Group: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Family Practice 2002; 3: 10.
7. Combe B., Swergold G., McLay J. et al.: Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology 2009; 48: 425-432.
8. da Costa B., Reichenbach S., Keller N. et al.: Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet 2016; 387: 2093-2105.
9. Croom K., Siddiqui A.: Etoricoxib. A Review of its Use in the Symptomatic Treatment of Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis and Acute Gouty Arthritis. Drugs 2009; 69(11): 1513-1532.
10. Feng X., Tian M., Zhang W. et. al.: Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis. PLoS One 2018; 13(1): e0190798.
11. van der Heijde D., Ramiro S., Landewé R. et. al.: 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann. Rheum. Dis. 2017; 76(6): 978-991.
12. Lanas A., Boers M, Nuevo J.: Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. Ann. Rheum. Dis. 2015; 74: 675-681.
13. MacDonald T., Hawkey C., Ford I. et al.: Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). Eur. Heart J. 2017; 38: 1843-1850.
14. Matsumoto A., Melian A., Mandel D. et. al.; and the Etoricoxib Rheumatoid Arthritis Study Group: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol. 2002; 29: 1623-1630.
15. Moore R., Derry S, Aldington D. et. al.: Single dose oral analgesics for acute postoperative pain in adults – an overview of Cochrane reviews. Cochrane Database Syst. Rev. 2015; (9): CD008659.
16. Nissen S., Yeomans N., Solomon D. et al.: Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N. Engl. J. Med. 2016; 375: 2519-2529.
17. Puopolo M., Boice J., Fidelholtz J. et. al.: A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with Osteoarthritis. Osteoarthritis Cartilage 2007; 15: 1348-1356.
18. Richy F., Bruyere O., Ethgen O. et al.; on behalf of the WHO Collaborating Centre for Public Health Aspects of Osteoarticular Disorders, Liège, Belgium: Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann. Rheum. Dis. 2004; 63: 759-766.
19. Ruschitzka F., Borer J., Krum H. et. al.: Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur. Heart J. 2017; 38(44): 3282-3292.
20. Scott P., Kingsley G., Smith C. et al.: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann. Rheum. Dis. 2007; 66: 1296-1304.
21. Silverstein F., Faich G., Goldstein J. et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 1247-1255.
22. Stam W., Jansen J., Taylor S.: Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison. Open Rheumatol. J. 2012; 6: 6-20.
23. Trelle S., Reichenbach S., Wandel S. et al.: Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: c7086.
24. Zhang W., Moskowitz R., Nuki G. et al.: OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence- based, expert consensus Guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.